BeOne Medicines Ltd.

For the period ended Jun 30, 2026. Filed Aug 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 5, 2026

ONC$417.33+2.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 5. Other Information

(a)

Effective as of August 3, 2026, the Swiss Articles were amended to reflect changes in the Company’s total issued share capital resulting from the issuance to one of the Company’s wholly-owned subsidiaries of 866,073 of the Company’s fully paid-up registered shares with a nominal value of $0.0001 each, which are being used in connection with the Company’s share delivery obligations from time to time pursuant to its equity benefit plans. As a result of this amendment, the Swiss Articles now reflect a share capital of $154,184.1971 divided into 1,541,841,971 fully paid-up registered shares, and the capital band provision contained therein has been updated.

A copy of the Company’s amended Swiss Articles is attached hereto as Exhibit 3.1 and is incorporated herein by reference.

(c)

The following table describes for the quarterly period covered by this report each trading arrangement for the purchase or sale of the Company’s securities adopted, modified orterminated by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), or a “Rule 10b5-1 trading arrangement,” or (2) a “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K):

Name (Title)	Action Taken (Date of Action)	Type of Trading Arrangement	Nature of Trading Arrangement	Duration of Trading Arrangement	Aggregate Number of Securities
Chan Lee(Senior Vice President, General Counsel)	Adoption(May 29, 2026)	Rule 10b5-1 trading arrangement	Sale	August 28, 2027	Up to 9,353 ADSs plus up to such additional number of ADSs subject to restricted share units (“RSUs”) equal to the net number of ADSs resulting from applicable RSU vestings after sell-to-cover for withholding tax.
Dr. Xiaodong Wang(Co-Founder and Director)	Adoption(June 9, 2026)	Rule 10b5-1 trading arrangement	Sale	September 8, 2027	Stock options and RSUs equaling up to 131,370 ADSs.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.